MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement

MetaVia (Nasdaq: MTVA) announced on December 22, 2025 that it received Nasdaq notice dated December 19, 2025 confirming the company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2).

Rhea-AI Summary

MetaVia (Nasdaq: MTVA) announced on December 22, 2025 that it received Nasdaq notice dated December 19, 2025 confirming the company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2).

The notice states MetaVia also satisfies all other applicable Nasdaq listing criteria and that the related listing matter has been closed on the Nasdaq Capital Market.

Positive

• Regained Nasdaq compliance with minimum bid price on Dec 19, 2025
• Listing matter formally closed by Nasdaq for continued Nasdaq Capital Market listing

Negative

• None.

Argus Dec 22 session

+11.60% close to close Open Argus

Details

News Market Reaction – MTVA

In the Dec 22 session, MTVA gained 11.60%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +11.6% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +11.6% in the session following this news. A strong positive reaction aligns with the resolution of a key listing overhang. Regaining Nasdaq’s minimum bid compliance under Rule 5550(a)(2) follows earlier steps like the 1-for-11 reverse split and may have reduced perceived delisting risk. Historically, MetaVia’s clinical wins drew buying while financial and structural actions were sold. If gains became extended, investors could have watched whether interest persisted given the stock’s position below its 200-day moving average.

Key Figures

Nasdaq notice date: December 19, 2025 Listing rule: Rule 5550(a)(2)

Nasdaq notice date

December 19, 2025

Date Nasdaq confirmed MetaVia regained minimum bid price compliance

Listing rule

Rule 5550(a)(2)

Nasdaq minimum bid price requirement referenced in the notice

Historical Context

5 past events · Latest: Dec 02

5 events

1. Dec 02

   Reverse stock split

   24h Move

   -20.1%

   1-for-11 reverse split aimed at meeting Nasdaq listing requirements.

2. Nov 07

   Phase 2a data

   24h Move

   +6.8%

   Positive Phase 2a vanoglipel data in presumed MASH at AASLD 2025.

3. Nov 06

   Earnings and update

   24h Move

   -15.0%

   Q3 2025 results and pipeline update including DA-1726 and vanoglipel.

4. Nov 04

   Conference data

   24h Move

   +8.0%

   Phase 1 and preclinical DA-1726 data presented at ObesityWeek 2025.

5. Oct 27

   Poster announcement

   24h Move

   -1.4%

   Announcement of vanoglipel poster presentation at AASLD Liver Meeting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq's minimum bid price requirement, the nasdaq capital market

2 terms

nasdaq's minimum bid price requirement regulatory

"it received formal notice from The Nasdaq Stock Market, LLC ... that the Company has regained compliance with Nasdaq's minimum bid price requirement"

A rule requiring a stock listed on the Nasdaq exchange to maintain a minimum quoted bid price (commonly $1) over a set period to stay listed. Think of it like a membership minimum: if a stock consistently trades below that threshold, Nasdaq may warn the company and eventually remove the listing, which can reduce visibility, liquidity and the ease with which investors buy or sell the shares.

the nasdaq capital market regulatory

"continued listing on The Nasdaq Capital Market. As a result, the listing matter has been closed."

A tier of the Nasdaq stock exchange that hosts smaller or early-stage public companies that meet defined listing standards for size, share price and governance. Think of it as a particular shelf in a store for emerging brands: it gives investors a centralized place to find and trade these stocks while signaling that the companies meet basic regulatory and financial rules. Investors watch it for growth opportunities and higher volatility compared with larger markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that on December 19, 2025, it received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Company has regained compliance with Nasdaq's minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market. As a result, the listing matter has been closed.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Contacts:

MetaVia
Marshall H. Woodworth
Interim Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302647630.html

SOURCE MetaVia Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MetaVia (MTVA) announce on December 22, 2025 about Nasdaq compliance?

MetaVia announced it received notice dated Dec 19, 2025 confirming it has regained compliance with Nasdaq's minimum bid price requirement.

Does MetaVia (MTVA) remain listed on the Nasdaq Capital Market after Dec 19, 2025?

Yes. The company said it satisfies Nasdaq listing criteria and the related listing matter has been closed.

What Nasdaq rule did MetaVia (MTVA) regain compliance with on Dec 19, 2025?

MetaVia regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement.

Will MetaVia (MTVA) face immediate delisting after the Nasdaq notice on Dec 19, 2025?

No. The notice indicates MetaVia has regained compliance and the listing matter has been closed, not delisted.

Where can investors find the Nasdaq compliance notice for MetaVia (MTVA)?

Investors can review the company's regulatory filings and Nasdaq notices on the Nasdaq website and MetaVia investor relations disclosures.